Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
142 hedge funds and large institutions have $415M invested in Progenics Pharmaceuticals Inc in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 44 reducing their positions, and 21 closing their positions.
133% more call options, than puts
Call options by funds: $2.69M | Put options by funds: $1.16M
31% more capital invested
Capital invested by funds: $318M → $415M (+$97.1M)
5% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 44
4% less funds holding
Funds holding: 148 → 142 (-6)
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$6.47M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.73M |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$3.46M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$3.06M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$3.88M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.7M |
| 3 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$2.92M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$2.21M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.21M |
PGNX Hedge Fund Activity: Q2 2019 in Review
142 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2019, worth a combined $415M — up 31% from $318M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of PGNX and 18 opened new positions — a net loss of 3 holders — while 44 trimmed existing stakes and 46 added.
The largest buyer was Farallon Capital Management, adding an estimated $6.47M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $3.88M sold.
- 142 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2019, down from 148 in Q1 2019.
- Funds reported $415M of Progenics Pharmaceuticals Inc stock for Q2 2019, up 31% quarter-over-quarter.
- 18 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2019 and 21 closed out, a net change of -3 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q2 2019 was Farallon Capital Management, an estimated $6.47M added.
- The largest Progenics Pharmaceuticals Inc seller in Q2 2019 was Renaissance Technologies, an estimated $3.88M sold.
Based on aggregated 13F filings for Q2 2019.